153 related articles for article (PubMed ID: 26595604)
1. Non-invasive in vivo imaging of early metabolic tumor response to therapies targeting choline metabolism.
Mignion L; Danhier P; Magat J; Porporato PE; Masquelier J; Gregoire V; Muccioli GG; Sonveaux P; Gallez B; Jordan BF
Int J Cancer; 2016 Apr; 138(8):2043-9. PubMed ID: 26595604
[TBL] [Abstract][Full Text] [Related]
2. Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion-weighted MRI, choline spectroscopy and 18F-FLT PET imaging.
Karroum O; Mignion L; Kengen J; Karmani L; Levêque P; Danhier P; Magat J; Bol A; Labar D; Grégoire V; Bouzin C; Feron O; Gallez B; Jordan BF
Contrast Media Mol Imaging; 2013; 8(3):274-80. PubMed ID: 23606431
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion-weighted imaging.
Canese R; Pisanu ME; Mezzanzanica D; Ricci A; Paris L; Bagnoli M; Valeri B; Spada M; Venditti M; Cesolini A; Rodomonte A; Giannini M; Canevari S; Podo F; Iorio E
NMR Biomed; 2012 Apr; 25(4):632-42. PubMed ID: 22020805
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
Al-Saffar NM; Troy H; Ramírez de Molina A; Jackson LE; Madhu B; Griffiths JR; Leach MO; Workman P; Lacal JC; Judson IR; Chung YL
Cancer Res; 2006 Jan; 66(1):427-34. PubMed ID: 16397258
[TBL] [Abstract][Full Text] [Related]
5. Multimodal assessment of early tumor response to chemotherapy: comparison between diffusion-weighted MRI, 1H-MR spectroscopy of choline and USPIO particles targeted at cell death.
Radermacher KA; Magat J; Bouzin C; Laurent S; Dresselaers T; Himmelreich U; Boutry S; Mahieu I; Vander Elst L; Feron O; Muller RN; Jordan BF; Gallez B
NMR Biomed; 2012 Apr; 25(4):514-22. PubMed ID: 21874657
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive monitoring of radiation-induced treatment response using proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonance imaging in a colorectal tumor model.
Seierstad T; Røe K; Olsen DR
Radiother Oncol; 2007 Nov; 85(2):187-94. PubMed ID: 17937968
[TBL] [Abstract][Full Text] [Related]
7. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
Jeon TY; Kim CK; Kim JH; Im GH; Park BK; Lee JH
Br J Radiol; 2015 Sep; 88(1053):20150163. PubMed ID: 26133222
[TBL] [Abstract][Full Text] [Related]
8. Intravoxel incoherent motion MRI for monitoring the therapeutic response of hepatocellular carcinoma to sorafenib treatment in mouse xenograft tumor models.
Lee Y; Lee SS; Cheong H; Lee CK; Kim N; Son WC; Hong SM
Acta Radiol; 2017 Sep; 58(9):1045-1053. PubMed ID: 28273738
[TBL] [Abstract][Full Text] [Related]
9. Prediction of pathologic response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and MRS.
Shin HJ; Baek HM; Ahn JH; Baek S; Kim H; Cha JH; Kim HH
NMR Biomed; 2012 Dec; 25(12):1349-59. PubMed ID: 22566277
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance spectroscopy for detection of choline kinase inhibition in the treatment of brain tumors.
Kumar M; Arlauckas SP; Saksena S; Verma G; Ittyerah R; Pickup S; Popov AV; Delikatny EJ; Poptani H
Mol Cancer Ther; 2015 Apr; 14(4):899-908. PubMed ID: 25657334
[TBL] [Abstract][Full Text] [Related]
11. In vivo MR spectroscopy predicts high tumor grade in endometrial cancer.
Ytre-Hauge S; Esmaeili M; Sjøbakk TE; Grüner R; Woie K; Werner HM; Krakstad C; Bjørge L; Salvesen ØO; Stefansson IM; Trovik J; Bathen TF; Haldorsen IS
Acta Radiol; 2018 Apr; 59(4):497-505. PubMed ID: 28927296
[TBL] [Abstract][Full Text] [Related]
12. Proton MR Spectroscopy and Diffusion MR Imaging Monitoring to Predict Tumor Response to Interstitial Photodynamic Therapy for Glioblastoma.
Toussaint M; Pinel S; Auger F; Durieux N; Thomassin M; Thomas E; Moussaron A; Meng D; Plénat F; Amouroux M; Bastogne T; Frochot C; Tillement O; Lux F; Barberi-Heyob M
Theranostics; 2017; 7(2):436-451. PubMed ID: 28255341
[TBL] [Abstract][Full Text] [Related]
13. Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.
Beloueche-Babari M; Jamin Y; Arunan V; Walker-Samuel S; Revill M; Smith PD; Halliday J; Waterton JC; Barjat H; Workman P; Leach MO; Robinson SP
Br J Cancer; 2013 Sep; 109(6):1562-9. PubMed ID: 23942066
[TBL] [Abstract][Full Text] [Related]
14. Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas.
Acciardo S; Mignion L; Joudiou N; Bouzin C; Baurain JF; Gallez B; Jordan BF
Oncotarget; 2018 Mar; 9(24):16832-16846. PubMed ID: 29682188
[TBL] [Abstract][Full Text] [Related]
15. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
[TBL] [Abstract][Full Text] [Related]
16. Integration of MRI and MRS approaches to monitor molecular imaging and metabolomic effects of trabectedin on a preclinical ovarian cancer model.
Canese R; Palombelli G; Chirico M; Sestili P; Bagnoli M; Canevari S; Mezzanzanica D; Podo F; Iorio E
NMR Biomed; 2019 Oct; 32(10):e4016. PubMed ID: 30375088
[TBL] [Abstract][Full Text] [Related]
17. Monitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI.
Mignion L; Dutta P; Martinez GV; Foroutan P; Gillies RJ; Jordan BF
Cancer Res; 2014 Feb; 74(3):686-94. PubMed ID: 24285723
[TBL] [Abstract][Full Text] [Related]
18. Proton magnetic resonance spectroscopy and diffusion-weighted imaging in intracranial cystic mass lesions.
Lai PH; Hsu SS; Ding SW; Ko CW; Fu JH; Weng MJ; Yeh LR; Wu MT; Liang HL; Chen CK; Pan HB
Surg Neurol; 2007; 68 Suppl 1():S25-36. PubMed ID: 17963918
[TBL] [Abstract][Full Text] [Related]
19. Modulation of choline kinase activity in human cancer cells observed by dynamic 31P NMR.
Gabellieri C; Beloueche-Babari M; Jamin Y; Payne GS; Leach MO; Eykyn TR
NMR Biomed; 2009 May; 22(4):456-61. PubMed ID: 19156696
[TBL] [Abstract][Full Text] [Related]
20. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Smolle E; Taucher V; Petru E; Haybaeck J
Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
